O PE	25533			Confir	mation No.	P
FEB 2 2 2005 Under	the Paperwork Reduction Act of 1995	i. no person	s are required to respond to a collection Application Number Filing Date	nt and Trad on of inform 10/774 Februa	ry 6, 2004	-0031 ERCE
	Sed for all correspondence after initial	filing)	First Named Inventor Art Unit Examiner Name	Not Ye	Chupak, et al. et Known et Known	
Total Nu	mber of Pages in This Submission		Attorney Docket Number		PC25654A	
		ENC	LOSURES (Check all that	t apply)		
Arr Carr Exp	Fee Attached aendment/Reply After Final Affidavits/declaration(s) dension of Time Request bress Abandonment Request correst Abandonment Request correst Copy of Priority cument(s)	Rema]	After Allowance Communication to a Technology Center (TC) Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below): Return Postcard, Copies of references Cited on PTO SB/08B, Statement as Provided by 37 CFR 1.97(b) (2pgs)	
Re	sponse to Missing Parts/ omplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	NECES			YMENT TO DEPOSIT ACCOUNT	

Thereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:Commissioner for Patents, P.O.Box 1450, Alexandria, VA 22313-1450 on this date

Typed or printed

Signature

Date 21505

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Reg. No. 32,410

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

USPTO Fax No.

Firm

Individual Signature Date J. Michael Dixon

703-872-9306



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Application No

10/774,241

Applicant

Louis Chupak, et al

Filed

February 6, 2004

Title

Antibacterial Agents

TC/A.U.

Unkown

Examiner

Not Yet Known

Docket No.

PC 25654A

Customer No.

Confirmation No

28880

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Statement as Provided by 37 CFR 1.97(b)

Dear Sir:

The Applicants submit that a Supplemental Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of the first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

As such, the Applicants respectfully requests consideration of the enclosed Supplemental Information Disclosure Statement and request that all references cited herein be printed on the face of the patent upon grant of the Application.

A copy of the International Search Report and the Written Opinion of the International Searching Authority is enclosed for the Examiner's convenience.

It is understood by the Applicants that this paper requires no fee; however, authorization is given to charge any necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

Dated:

Respectfully submitted,

J. Michael Dixon

Registration No. 32,410

Warner-Lambert Company

2800 Plymouth Road

Ann Arbor, MI 48105

Telephone: (734) 622-1705 Facsimile: (734) 622-1553

28880 FEB 2 2 2005

Confirmation No.

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under Paragraphic Made Manager State of France 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known					
Application Number	10/774,241				
Filing Date	FEBRUARY 6, 2004				
First Named Inventor	Boyer et al				
Art Unit	Not Yet Known				
Examiner Name	Not Yet Known				
Attorney Docket Number	PC25654A				

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	No.1	Number-Kind Code ^{2 (if known)}	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevan Figures Appear
		US- 4,705,799	11-10-1987	Gregory	
		US- 5,043,443	08-27-1991	Carlson et al	
		US- 5,164,510	11-17-1992	Brickner	
		US- 5,182,403	01-26-1993	Brickner	
		US- 5,225,565	07-06-1993	Brickner	
		US- 5,231,188	07-27-1993	Brickner	
		US- 5,247,090	09-21-1993	Brickner	
		US- 5,529,998	06-25-1996	Habich et al	
		US- 5,547,950	08-20-1996	Hutchinson et al	
		US- 5,652,238	07-29-1997	Brickner et al	
		US- 5,684,023	11-04-1997	Riedl et al	
_		US- 5,688,792	11-18-1997	Barbachyn et al	
		US- 5,698,574	12-16-1997	Riedl et al	
		US- 5,792,765	08-11-1998	Riedl et al	
		US- 5,827,857	10-27-1998	Riedl et al	
		US- 5,843,967	12-01-1998	Riedl et al	
		US- 5,861,413	01-19-1999	Habich et al	
		US- 5,869,659	02-09-1999	Stolle et al	
		US- 5,952,324	09-14-1999	Barbachyn et al	

FOREIGN PATENT DOCUMENTS							
	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages		
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	⊤⁵	
		WO94/01110	01-20-1994	THE UPJOHN CO.			
		WO95/07271	03-16-1995	THE UPJOHN CO.			
•		WO96/13502	05-09-1996	THE UPJOHN CO.			
		WO96/23788	08-08-1996	PHARMACIA			
		WO96/35691	11-14-1996	PHARMACIA			
		WO97/30995	08-28-1997	ZENECA			

Examiner	 Date	
Signature	Considered	
4.5		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Approved for use through 07/31/2006, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number 10/774,241 Filing Date February 6, 2004 INFORMATION DISCLOSURE First Named Inventor L. Chupak et al STATEMENT BY APPLICANT Art Unit Not Yet Known (Use as many sheets as necessary) **Examiner Name** Not Yet Known Attorney Docket Number PC25654A

Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		^{US-} 5,990,136	11-23-1999	Barbachyn et al	
		US- 6,043,266	03-28-2000	Ennis et al	
		US- 6,069,145	05-30-2000	Betts	
		US-6,069,160	05-30-2000	Stolle et al	
		US- 6,110,936	08-29-2000	Gravestock	
		US- 6,166,056	12-26-2000	Thomas et al	
		^{US-} 6,194,441	02-27-2001	Roberts et al	
-		US- 6,239,152	05-29-2001	Gordeev et al	
		US- 6,239,283	05-29-2001	Gage	
		US- 6,689,769	02-10-2004	Gordeev et al	
		US-			

FOREIGN PATENT DOCUMENTS							
	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages		
		Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶	
·		WO99/03846	01-28-1999	BAYER			
		WO99/29688	06-17-1999	PHARMACIA			
		WO99/37641	07-29-1999	BAYER AKTIEN			
		WO99/37652	07-29-1999	BAYER AKTIEN			
		WO99/64417	12-16-1999	ZENECA			
		WO00/21960	04-20-2000	ZENECA			

Examiner	Date	
Signature	Considered	
-	1	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND**TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/774,241	
INEC	TOMATI	ON DIS	CLOSUDE	Filing Date	February 6, 2004	
INFORMATION DISCLOSURE				First Named Inventor	L. Chupak et al	
STATEMENT BY APPLICANT				Art Unit	Not Yet Known	
(Use as many sheets as necessary)		Examiner Name	Not Yet Known			
Sheet	3	of	8	Attorney Docket Number	PC25654A	

			U. S. PATENT D		
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	ļ	Number-Kind Code ^{2 (if known)}			r igures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
-		US-			
		US-			
		US-			
 		US-			
		US-			
-		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS							
	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear		
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)	MM-DD-YYYY			T	
		WO00/44741	08-03-2000	PHARMACIA			
		WO00/73301	12-07-2000	PHARMACIA		Г	
		WO01/40236	06-07-2001	ASTRAZENECA AB			
		WO01/81350	11-01-2001	ASTRAZENECA			
		WO02/096916	12-05-2002	ASTRAZENECA AB			
		WO02/059155	08-01-2002	University of Leeds			

Examiner	Date	1
Signature	Considered	
_		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

TO: Commissioner for Pace 1.90. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Officer	tile Faperwork Reduction	1 ACI OI 1995,	no persons are required to r	espond to a collection of informat	tion unless it contains a valid OMB control number.
Subs	titute for form 1449/PTO			Cor	mplete if Known
				Application Number	10/774,241
INI	FORMATIO	או חופר	OSLIDE	Filing Date	February 6, 2004
				First Named Inventor	L. Chupak et al
S	TATEMENT			Art Unit	Not Yet Known
	(Use as many sh	neets as nec	essary)	Examiner Name	Not Yet Known
Sheet	4	of	8	Attorney Docket Number	PC25654A

			U. S. PATENT D	OCUMENTS		
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (# known)}	Document Number Publication Date MM-DD-YYYY		Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	 	US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
•		US-				
		US-		•		
		US-				
		US-				
		US-				
		US-				
		US-		•		
		US-				
		US-				
		US-				
	1	US-				

	FORE	IGN PATENT DOC	JMENTS		
Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
	Country Code ³ "Number ⁴ "Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T
	WO03/006440	01-23-2003	PHARMACIA		
	EP0417044A2	08-29-1990	CIBA-GEIGY AG		
	EP0697408B1	08-10-1995	MERCK PATENT		
 					L
					L
				1	

Examiner	 Date	
Signature	Considered	
	1	l .

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁸ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	e for form 1449/PTO	ruction Ac	x or 1995, no persons ar	e required to respond to a collection	of information unless it contains a valid OMB control number. Complete if Known
0110,,,11				Application Number	10/774,241
INFO	ORMATION	I DIS	CLOSURE	Filing Date	February 6, 2004
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	L. Chupak et al
	(Use as many she	ote se n	ecessard	Art Unit	Not Yet Known
	(OSC US Mully Sile	,c.s as n		Examiner Name	Not Yet Known
Sheet	5	of	8 .	Attorney Docket Number	PC25654A

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		ABDELAAL, et. al., "Synthesis of 1-[3-Methyl]-2(3H)-benzazolon-5- or 6-yl]-4-{4-[cis-2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl-methyl)-1,3-dioxolan-4-yl]methylene oxyphenyl]}piperazines" Journal of Heterocyclic Chem., 29, 1069, (1992).	
		BARBACHYN, et. al. "Identification of a Novel Oxazolidinone (U-100480) with Potent Antimycobacterial Activity." Journal of Medicinal Chemistry. 1996, 39, 680-685.	
		BLACHE, et. al. "Application of the Mercuric Acetate-Edetic Acid Oxidation Method To The Synthesis of 11-Aza-1,2,3,4,5,6,7,12bpOctahydroindolo[2,3-a]Quinolizines." Heterocycles, Vol. 45, No.1, Pp.57-69, 1997	
		BODOR, Nicholas and J. Hillis Miller, "Novel Approaches in Prodrug Design." Drugs of the Future Vol. VI, No. 3, 1981, pp. 165-182.	
		YAMAMOTO, Yutaka, and Akihiko Yanagi. "Studies on Organometallic Compounds, II Facile and Convenient Method for the Synthesis of Iodoazines through Iododestannation of Trimethylstannylazines." Chem Pharm. Bull. 30(5) 1731-1737(1982).	
		BRICKNER, et. al. "Synthesis and Antibacterial Activity of U-100592 and U-100766, Two Oxazolidinone Antibacterial Agents for the Potential Treatment of Multidrug-Resistant Gram-Positive Bacterial Infections." Journal of Medicinal Chemistry. 1996, 39, 673-679.	
		BUNDGAARD, Hans. "Design of prodrugs: Bioreversible derivatives for various functional groups and chemical entities." Design of Prodrugs, Chapter 1, 1985.	
		CAVA, Michael P. and Matthew I. Levinson. "Thionation Reactions of Lawesson's Reagents." Tetrahedron Vol. 41, No. 22, pp. 5061-5087, 1985.	
<u> </u>		CLARK, Robert L. and Arsenio A. Pessolano. "Synthesis of Some Substituted Benzoxazolones." Journal of the American Chemical Society." Vol. 80, pp. 1662, 1958.	
		COMINS, et. al. "Preparation of 2,6-Disubstituted 2,3-Dihydro-4-pyridones: Dehydrogenation of Trimethylsilyl Enol Ethers with Palladium (II) Acetate." Tetrahedron Letters, Vol. 36, No. 52, pp. 9449-9452, 1995.	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitut	e for form 1449/PTO			Complete if Known		
				Application Number	10/774,241	
INFO	DRMATION	DIS	CLOSURE	Filing Date	February 6, 2004	
STA	TEMENT B	Y A	PPLICANT	First Named Inventor	L. Chupak et al	
	(Use as many she	ate se ni	acessand	Art Unit	Not Yet Known	
	(USC as many sne		acessary)	Examiner Name	Not Yet Known	
Sheet	6	of	8	Attorney Docket Number	PC25654A	

	,	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		COMINS, et. al. "Regio- and Stereoselective Addition of Nucleophiles to 1- Phenoxycarbonyl-2,3-Dihydropyridium Salts." Heterocycles, Vol. 37, No. 2, 1994, pgs 1121-1140.	
		DEHMLOW, Eckehard, and Ralf Westerheide. "Studies Towards 3,4-Dimethoxy-1-Methyl-1,2-Dihydropyridine, so-called Arccolidine, or its Tautomers." Heterocycles, Vol. 37, No. 1, 1994, pgs. 355-366.	
		DIEZ, et. al. "Preparation of a New Chiral 5,6-Dihydropyridinium Synthon." Heterocycles, Vol. 31, No. 3, 1990, pgs., 485-492.	
		DODD, Dharmpal and Allan Oehlschlager. "Efficient Route to the Synthesis of C-2, C-3 Substituted 4-Piperidones." Tetrahedron Letters, Vol. 32, No. 30, pp. 3643-3646, 1991.	
		EVANS, et. al. "Regioselective Preparation of a,B-Unsaturated Ketones via the Direct Dehydrogeantion of Triisopropylsilyl Enol Ethers." Tetrahedron Letters, Vol. 36, No. 23, pp. 3985-3988, 1995.	
		GAGE, et. al. "Stereodivergent synthesis of sulfoxide-containing oxazolidinone antibiotics." Tetrahedron Letters, 41 (2000) 4301-4305.	
		GUERRY Philippe and Reinhard Neier, "Photochemical Cycloadditions to 5,6-Dihydro-4-pyridones." Chimia 41 (1987) No. 10 (October), pgs., 341-342.	
		GUERRY, Philippe and Reinhard Neier. "Reduktion von 4-Pyridinonen." Synthesis, June 1984 pp. 485-488.	
		HAIDER, et. al. "140. Synthesis of 4-Oxo-1,2,3,4-tetrahydropyridine (2,3-Dihydro-4(1H)pyridinone)." Helvetica Chimica Acta - Vol. 58, Fasc. 5 (1975) - Nr. 139 - 140 pp. 1287-1292.	
:		HERRINTON, et. al. " Iodination and Metal Halogen Exchange of Aromatic Compounds: An Improved Preparation of a Key Oxazolidinone Antibiotic Intermediate." Organic Process Research and Development 2001, 5, 80-83.	

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.

Commissioner for Patents P.O. Rox 1450 Alexandria, VA 22313-1450. Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitut	te for form 1449/PTO	·			Complete if Known
Judama	10 10 10 10 10			Application Number	10/774,241
INFO	DRMATION	I DIS	CLOSURE	Filing Date	February 6, 2004
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	L. Chupak et al
	(Use as many she	aate ae n	neaseand	Art Unit	Not Yet Known
	(USU as many sine	ous as m	acessary)	Examiner Name	Not Yet Known
Sheet	7	of	8	Attorney Docket Number	PC25654A

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ISHII, et. al. "Rhodium-Catalyzed Reaction of N-Acylpiperazines with CO and Ethylene, Carbonylation at a C-H Bond Directed by an Amido Group." Tetrahedron Letters, Vol. 38, No. 43, pp. 7565-7568, 1997.	
		KIRSCHBAUM, Stephen, and Herbert Waldmann. "Construction of the Tricyclic Benzoquinolizine Ring System by Combination of a Tandem Mannich-Michael Reaction with a Heck Reaction." Tetrahedron Letters, Vol. 38, No. 16, pp. 2829-2832, 1997.	
		KIRSCHBAUM, Stepen, and Herbert waldmann. "Three-Step Acces to the Tricyclic Benzo[a]quinolizine Ring System." Journal of Organic Chemistry. 1998, 63, 4936-4946.	
		LOCK, Ralf, and Herbert Waldmann. "Asymetric Synthesis of Highly Functionalized Tetracyclic Indole Bases Embodying the Basic Skeleton of Yohimbinep and Reserpine Type Alkaloids." Tetrahedron Letters, vol. 37, No. 16, pp. 2753-2756, 1996.	
		LOCK, Ralf, and Herbert Waldmann. "Enantioselective Construction of Highly Fuctionalized Indoloquinolizines Congeners to Polycyclic Indole Alkaloids." Chem. Eur. J. 1997, 3, No. 1, pp. 143-151.	
		MAI, et. al. "N-[4-(1,1'-Biphenylyl)Methyl]-4-(4-Thiomorpholinylmethyl) Benzenamines, a New Class of Synthetic Antituberculosis Agents Active Against Mycobacterium Avium." Medicinal Chemistry Research, 9:3 (1999) 149-161.	
		NOTARI, Robert E., "Theory and Practice of Prodrug Kinetics." Methods in Enzymology, Vol. 112, 1985, pp. 309-323.	
		REGGELIN, Michael, and Cornelia Zur, "Sulfoximines; Structures, Properties and Synthetic Applications." Synthesis, 2000, No. 1, 1-64.	
		ROUSH, William R., and Bradley B. Brown. "Enantioselective Syntehsis of 2-Alkyl-5-methylene-1,3-dioxolan-4-ones and Exo-Selective Diels-Alder Reactions with Cyclopentadiene." Journal of Organic Chemistry. 1992, 57, 3380-3387.	
		STUTZ, P, and PA Stadler, "A Novel Approach to Cyclic b-Carbonyl-Enamines 7,8 - Lysergic Acid Derivatives Via The Polonovski Reaction." Tetrahedron Letters No. 51, pp. 5095 - 5098, 1973.	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/774,241	
INFO	DRMATION	DIS	CLOSURE	Filing Date	February 6, 2004	
STA	STATEMENT BY APPLICANT			First Named Inventor	L. Chupaket al	
	(lice as many she	ate se n	ecessan/i	Art Unit	Not Yet Known	
(Use as many sheets as necessary)				Examiner Name	Not Yet Known	
Sheet	8	of	8	Attorney Docket Number	PC25654A	

Examiner	Cite	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of	
Initials*	No. ¹	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		WALDMANN et. al. "Asymmetric Synthesis of Indolo[2,3-a]quinolizidin-2-onesCongeners to Yohimbine-Type Alkaloids." Tetrahedron Vol. 49, No. 2, 1993, Pp. 397-416.	
		English Abstract for GUERRY, Philippe "Reduktion von 4-Pyridinonen"	
		English Abstract for EP0417044A2	
		English Abstract for EP0697408B1	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Bernges, Cynthia

From:

Bott, Cindy

Sent:

Sunday, February 13, 2005 10:03 PM

To:

Bernges, Cynthia

Subject:

FW: 3MGA methods paper

Please get me a copy of the reference Doug cites below. Thanks.

Cindy

-----Original Message-----

From:

Gage, Douglas

Sent:

Thursday, February 10, 2005 6:29 PM

To:

Bott, Cindy

Subject:

3MGA methods paper

Hi Cindy,

I was unable to get an electronic version for some reason. Here is the reference:

Kelly, RI (1993) Quantification of 3-methylglutaconic acid in urine, plasma and amniotic fluid by isotope-dilution gas chromatography/mass spectrometry. Clin. Chim Acta 220:157-164.

Doug